Across the EU and beyond, ACE-031, in its 1 milligram formulation , is being evaluated as a potential treatment for certain neurological conditions . Clinical trials in locations including Deutschland and France are assessing its efficacy on treatment response. Organizations throughout Europe are keeping a watch on the advancement of ACE-031, with